Persistence with Early-Line Abatacept versus Tumor Necrosis Factor-Inhibitors for Rheumatoid Arthritis Complicated by Poor Prognostic Factors.

In a post hoc analysis of AMPLE, the authors reported that in patients with early RA and poor prognostic factors, abatacept showed a trend toward greater efficacy compared with adalimumab. 26 Earlier AMPLE analyses had demonstrated fewer abatacept patients discontinued therapy due to adverse events than adalimumab patients. 27 In the AGREE trial, patients with rapidly-progressing RA and poor prognostic factors who received abatacept p

also in 53,322 other papers